脱髓鞘疾病患者血清中的抗髓鞘相关糖蛋白抗体。

Anti-myelin-associated glycoprotein antibody in sera from patients with demyelinating diseases.

作者信息

Sato S, Baba H, Inuzuka T, Miyatake T

出版信息

Acta Neurol Scand. 1986 Aug;74(2):115-20. doi: 10.1111/j.1600-0404.1986.tb04636.x.

DOI:10.1111/j.1600-0404.1986.tb04636.x

Abstract

An enzyme-linked immunosorbent assay (ELISA) was developed for quantitating anti-myelin-associated glycoprotein (MAG) IgM antibody in human sera. Absorbance values of anti-MAG antibody were higher than 0.2 at 1:80 of serum dilution in sera from some patients with demyelinating diseases of the central or peripheral nervous systems including multiple sclerosis, subacute sclerosing panencephalitis, Guillain-Barré syndrome, chronic relapsing polyradiculoneuritis and carcinomatous polyneuropathy and also some patients with autoimmune diseases such as collagen diseases and myasthenia gravis. However, absorbance values of anti-MAG antibody in sera from control individuals and patients with some other neurological diseases were less than 0.2 and considered as negative. Because of the reported existence of a cross antigenicity between MAG and lymphocyte, and especially natural killer cells, the possibility of the functional importance of anti-MAG antibody on cellular immunity is discussed with particular reference to the demyelinating diseases.

摘要

已开发出一种酶联免疫吸附测定法（ELISA），用于定量检测人血清中的抗髓鞘相关糖蛋白（MAG）IgM抗体。在包括多发性硬化症、亚急性硬化性全脑炎、格林-巴利综合征、慢性复发性多神经根炎和癌性多神经病等中枢或周围神经系统脱髓鞘疾病患者以及一些自身免疫性疾病（如胶原病和重症肌无力）患者的血清中，血清稀释度为1:80时抗MAG抗体的吸光度值高于0.2。然而，对照个体和其他一些神经系统疾病患者血清中抗MAG抗体的吸光度值小于0.2，被视为阴性。由于有报道称MAG与淋巴细胞尤其是自然杀伤细胞之间存在交叉抗原性，因此特别参照脱髓鞘疾病讨论了抗MAG抗体对细胞免疫功能重要性的可能性。